In 2014, Choi et al. pioneered the utilization of AD brain organoids as a drug screening platform, demonstrating that β−/γ-secretase modulators simultaneously reduce Aβ deposition and tau pathology (Choi et al., 2014), providing crucial experimental evidence for AD therapeutics. Here, MAPT is linked to Alzheimer disease.